PMID- 23357152
OWN - NLM
STAT- MEDLINE
DCOM- 20130918
LR  - 20171116
IS  - 1878-5050 (Electronic)
IS  - 1567-5688 (Linking)
VI  - 14
IP  - 1
DP  - 2013 Jan
TI  - Iron deficiency and its management in patients undergoing lipoprotein apheresis. 
      Comparison of two parenteral iron formulations.
PG  - 115-22
LID - S1567-5688(12)00023-2 [pii]
LID - 10.1016/j.atherosclerosissup.2012.10.012 [doi]
AB  - OBJECTIVES: There is evidence of iron deficiency (ID) in patients treated with 
      lipoprotein apheresis. Aim of this study was to assess ID in apheresis patients 
      and to study its management comparing safety and efficacy of two approved 
      intravenous (i.v.) iron formulations. METHODS: Inclusion criteria were defined as 
      a) serum ferritin < 300 mug/l and transferrin saturation < 20%, b) ferritin < 100 
      mug/l. Both iron deficient alone and ID anemic (IDA) patients were included. Other 
      causes for anemia were ruled out by thorough history-taking and examination/blood 
      tests. Patients were treated with six different lipoprotein apheresis methods: 
      DALI, Liposorber D, TheraSorb LDL, HELP, MONET and Lipidfiltration. 50 patients 
      were randomized to either ferric carboxymaltose (FCM, 500-1000 mg as single shot 
      infusion over 20 min) or ferric gluconate (FG, 62.5 mg once weekly). RESULTS: 50 
      of 67 patients of our Lipoprotein Apheresis Center showed iron deficiency. Both 
      i.v. iron formulations studied were equally safe (no serious adverse events 
      (SAEs), 6 patients/group showed adverse events (AEs)) and both effective 
      (clinically and with respect to laboratory data) in lipoprotein apheresis 
      patients, however FCM led to a more rapid and steeper rise of iron parameters. 
      CONCLUSIONS: ID and IDA are common findings in lipoprotein apheresis patients. 
      The pathogenesis remains yet poorly understood and is probably multifactorial. 
      Differential diagnosis of ID/IDA is as essential as differential therapy. Handled 
      with care, older i.v. iron preparations like FG appear to be safe and effective 
      in lipoprotein apheresis patients. However, novel formulations like FCM can be 
      administered rapidly at higher doses due to high complex stability, allowing 
      faster filling of iron stores. Newer laboratory parameters (Reticulocyte-He, 
      low/medium/high fluorescence reticulocytes (LFR/MFR/HFR)) assessing iron status 
      may be helpful in early detection of ID and in monitoring iron replacement 
      therapy.
CI  - Copyright (c) 2012. Published by Elsevier Ireland Ltd.
FAU - Schatz, U
AU  - Schatz U
AD  - Department of Internal Medicine III, University Hospital Carl Gustav Carus 
      Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. 
      Ulrike.Schatz@uniklinikum-dresden.de
FAU - Arneth, B
AU  - Arneth B
FAU - Siegert, G
AU  - Siegert G
FAU - Siegels, D
AU  - Siegels D
FAU - Fischer, S
AU  - Fischer S
FAU - Julius, U
AU  - Julius U
FAU - Bornstein, S R
AU  - Bornstein SR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Atheroscler Suppl
JT  - Atherosclerosis. Supplements
JID - 100973461
RN  - 0 (Biomarkers)
RN  - 0 (Ferric Compounds)
RN  - 0 (Hematinics)
RN  - 0 (Lipoproteins)
RN  - 0 (Transferrin)
RN  - 6897GXD6OE (ferric carboxymaltose)
RN  - 69-79-4 (Maltose)
RN  - 9007-73-2 (Ferritins)
RN  - W108RK810P (ferric gluconate)
SB  - IM
MH  - Aged
MH  - Anemia, Iron-Deficiency/blood/diagnosis/*drug therapy/etiology
MH  - Biomarkers/blood
MH  - *Blood Component Removal/adverse effects
MH  - Chemistry, Pharmaceutical
MH  - Drug Administration Schedule
MH  - Dyslipidemias/blood/diagnosis/*therapy
MH  - Female
MH  - Ferric Compounds/*administration & dosage/adverse effects/chemistry
MH  - Ferritins/blood
MH  - Germany
MH  - Hematinics/*administration & dosage/adverse effects/chemistry
MH  - Humans
MH  - Infusions, Intravenous
MH  - Lipoproteins/*blood
MH  - Male
MH  - Maltose/administration & dosage/adverse effects/*analogs & derivatives/chemistry
MH  - Middle Aged
MH  - Time Factors
MH  - Transferrin/metabolism
MH  - Treatment Outcome
EDAT- 2013/01/30 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/01/30 06:00
PHST- 2013/01/30 06:00 [entrez]
PHST- 2013/01/30 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
AID - S1567-5688(12)00023-2 [pii]
AID - 10.1016/j.atherosclerosissup.2012.10.012 [doi]
PST - ppublish
SO  - Atheroscler Suppl. 2013 Jan;14(1):115-22. doi: 
      10.1016/j.atherosclerosissup.2012.10.012.